Allarity Therapeutics

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company was founded on April 4, 2021 and is headquartered in Boston, MA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.

NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.

ATTENTION ALLR SHAREHOLDERS: Investors who lost money on Allarity Therapeutics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ALLR Investors Can Join The Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm

Investors who lost money on Allarity Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - ALLR

NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR). Investors who purchased Allarity securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALLR.

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm!

NEW YORK, NY / ACCESSWIRE / July 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.

ALLR STOCK ALERT: Levi & Korsinsky Notifies Allarity Therapeutics, Inc. Investors of an Ongoing Investigation

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Allarity Therapeutics, Inc. (ALLR)

NEW YORK, NY / ACCESSWIRE / July 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR). Investors who purchased Allarity securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALLR.

ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm!

Shareholders that lost money on Allarity Therapeutics, Inc.(ALLR) should contact Levi & Korsinsky about Securities Fraud Investigation - ALLR

NEW YORK, NY / ACCESSWIRE / July 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.

ALLR ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Allarity Therapeutics, Inc. Shareholders Who Lost Money

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.

Allarity Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ALLR

Shareholders that lost money on Allarity Therapeutics, Inc. (ALLR) should contact Levi & Korsinsky about Securities Fraud Investigation - ALLR

Did Allarity Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ALLR

NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR). Investors who purchased Allarity securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALLR.

ALLR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm!

Boston (July 26, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, announced that its Board of Directors has decided to postpone the Annual Meeting of Stockholders, which was originally scheduled for 10:00 AM Eastern Time today, July 26, 2024.

Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting

NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.

Allarity Therapeutics, Inc. (ALLR) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates

LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ALLR Investors Have The Opportunity To Join The Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR). Investors who purchased Allarity securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALLR.

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm!

LOS ANGELES--(BUSINESS WIRE)--ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm.

ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

NEW YORK--(BUSINESS WIRE)---- $ALLR #ALLR--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Allarity Therapeutics, Inc. (NASDAQ: ALLR) resulting from allegations that Allarity Therapeutics, Inc. may have issued materially misleading business information to the investing public. So what: If you purchased Allarity securities you may be entitled to compensation without payment of any out of pocket fees or costs through a.

Rosen Law Firm Encourages Allarity Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – ALLR

NEW YORK, NY / ACCESSWIRE / July 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.

Lost Money on Allarity Therapeutics, Inc.(ALLR)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

Allarity Therapeutics (NASDAQ: ALLR ) stock is on the rise Wednesday as the clinical-stage biopharmaceutical company is encouraging its shareholders to vote in favor of a reverse stock split. Allarity Therapeutics put out a press release pushing for investors to approve the reverse stock split during an upcoming shareholder meeting.

ALLR Stock Alert: Allarity Therapeutics Pushes Shareholders to Back Reverse Split

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Allarity investments or would like to inquire about potentially pursuing claims to recover your loss under the federal se.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors

ATLANTA, July 24, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) complied with federal securities laws. On July 22, 2024, Allarity disclosed that it received a Wells Notice from the SEC concerning “the Company's disclosures regarding meetings with the United States Food and Drug Administration (the “FDA”) regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.” Following this news, the price of the Company's stock dropped.

Investigation Into Allarity Therapeutics, Inc. (ALLR) Announced by Holzer & Holzer, LLC

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) investors concerning the Company's possible violations of federal securities laws. On July 22, 2024, Allarity disclosed that it had received a Wells Notice from the U.S. Securities and Exchange Commission relating to the Company's statements regarding meetings with the U.S. Food and Drug Administration about the Company's.

News for Allarity Therapeutics Stock (ALLR)